Binds Receptor Patents (Class 424/143.1)
  • Patent number: 11904017
    Abstract: The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody. The methods of the present invention are useful for treating patients with hyperlipidemia and related conditions who are currently being treated with a therapeutic regimen comprising lipoprotein apheresis (e.g., LDL apheresis or Lp(a) apheresis).
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: February 20, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert C. Pordy, Garen Manvelian
  • Patent number: 11873330
    Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 16, 2024
    Assignee: Genentech, Inc.
    Inventors: Sunil Bhakta, Jagath R. Junutula
  • Patent number: 11820814
    Abstract: Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: November 21, 2023
    Assignees: GEMINI THERAPEUTICS SUB, INC., STICHTING SANQUIN BLOEDVOORZIENING
    Inventors: Scott Lauder, Tom Purcell, Sridhar Govindarajan, Taco Willem Kuijpers, Diana Wouters, Maria Clara Brouwer, Richard Benjamin Pouw, Taede Rispens, Ilse Jongerius, Gillian Dekkers
  • Patent number: 11813264
    Abstract: Materials and methods for modulating protease activated receptor 1 (PAR1) activity to alter myelination are provided.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: November 14, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Isobel A Scarisbrick, Hye-Sook Yoon, Kristen L. Drucker
  • Patent number: 11773163
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 3, 2023
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE STRASBOURG, ETABLISSEMENT FRANçAIS DU SANG (EFS)
    Inventors: Pierre Mangin, Christian Gachet
  • Patent number: 11713352
    Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: August 1, 2023
    Assignee: University of Zürich
    Inventors: Uwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
  • Patent number: 11667720
    Abstract: The present application concerns methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: March 1, 2023
    Date of Patent: June 6, 2023
    Assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Xiaoping Zhang, Kimio Terao
  • Patent number: 11655305
    Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: May 23, 2023
    Assignee: Genentech, Inc.
    Inventors: Virginia Paton, Anne Blackwood Chirchir, Pam Klein
  • Patent number: 11655297
    Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 23, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen LTD.
    Inventors: Lars Röse, Uwe Gritzan, Julia Hütter, Spencer Liang, Andrew Pow, John Hunter, Ofer Levy, Ilan Vaknin
  • Patent number: 11596690
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Qingyan Hu, Dingjiang Liu
  • Patent number: 11591394
    Abstract: The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated biological functions. The invention in particular relates to such compounds and polypeptides comprising or consisting of at least one single domain antibody, and wherein at least one single domain antibody specifically binds to CD1d. Also provided is for methods and use employing such compounds, polypeptides and/or single-domain antibodies.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: February 28, 2023
    Assignee: LAVA THERAPEUTICS N.V.
    Inventors: Johannes Jelle Van Der Vliet, Tanja Denise De Gruijl, Hendrik Marinus Willem Verheul, Renée Cornelia Gerarda De Bruin, Roeland Lameris
  • Patent number: 11591392
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: February 28, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong
  • Patent number: 11572420
    Abstract: Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% ?-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In at least one embodiment, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: February 7, 2023
    Assignee: TISSUE REPAIR LTD
    Inventors: Anthony Charara, Mark Deacon Shaw
  • Patent number: 11553877
    Abstract: A CPU of a health management apparatus functions as an acquisition unit, a first derivation unit, and a screen output control unit. The acquisition unit acquires a body-fat percentage which is an obesity parameter indicating the degree of obesity of a target pet and bone density which is a bone parameter indicating the degree of bone strength of the target pet. The first derivation unit derives health conditions of the target pet on the basis of a correlation between the body-fat percentage and the bone density. A screen output control unit performs control to output a medical examination result display screen on which the health conditions are displayed.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: January 17, 2023
    Assignee: FUJIFILM CORPORATION
    Inventor: Yasuhisa Kaneko
  • Patent number: 11518815
    Abstract: The application provides anti-ROR1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: December 6, 2022
    Assignees: SYSTIMMUNE, INC., BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD.
    Inventors: Ole Olsen, Phil Tan, Dong Xia, David Jellyman, Brian Kovacevich, Bill Brady, Blair Renshaw, Zeren Gao, Yi Zhu
  • Patent number: 11498969
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: November 15, 2022
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Patent number: 11498968
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Cannarile, Anna-Maria Jegg, Francesca Michielin, Carola Ries, Dominik Ruettinger, Martin Weisser
  • Patent number: 11492411
    Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: November 8, 2022
    Assignee: Amgen Fremont Inc.
    Inventors: Richard F. Weber, Xiao Feng, Orit Foord, Larry L. Green, Jean M. Gudas, Bruce A. Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose R. F. Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal Singh Kang, Chadwick Terence King, Scott L. Klakamp, Qiaojuan Jane Su
  • Patent number: 11473150
    Abstract: The present invention relates to methods for detecting, diagnosing, prognosing, monitoring, and treating a patient with hepatocellular carcinoma. In particular, the invention provides diagnostic markers for the detection and treatment of patients who would benefit from immunotherapy, i.e., patient who would be most responsive to immunotherapy.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: October 18, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Daniela Sia, Josep Maria Llovet I Bayer, Augusto Villanueva-Rodriguez
  • Patent number: 11419318
    Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TRKB locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TRKB locus express a human TRKB protein or a chimeric transthyretin protein, fragments of which are from human TRKB. Methods are provided for using such non-human animals comprising a humanized TRKB locus to assess in vivo efficacy of human-TRKB-targeting reagents such as nuclease agents designed to target human TRKB.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: August 23, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Alexander O. Mujica, Yajun Tang, Jeffrey D. Lee, Min Gao, Susan D. Croll, Lynn Macdonald, Ying Hu, Carmelo Romano
  • Patent number: 11421034
    Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: August 23, 2022
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
  • Patent number: 11384142
    Abstract: This invention concerns methods of treating a patient diagnosed with a platinum-resistant ovarian cancer comprising administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 12, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: David Bollag, Corrado Bernasconi
  • Patent number: 11351229
    Abstract: The present invention provides methods of treating infantile spasms in a subject in need thereof. In certain embodiments, the method comprises administering to the subject both vigabatrin (VGB) and insulin-like growth factor 1 (IGF-1), a biologically active fragment thereof, or any derivative thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: June 7, 2022
    Assignee: Baylor College of Medicine
    Inventors: John W. Swann, Chong L. Lee, John T. Le, James D. Frost, Jr.
  • Patent number: 11291722
    Abstract: The present invention relates to a vaccine composition comprising cyclic peptides of the present invention, antibodies to cyclic peptides, or an anticancer composition comprising them, and the vaccine composition of the present invention exhibit an inhibitory activity for metastasis of cancer. In addition, the antibodies of the present invention bind to the tumor-specific antigen TM4SF5 with high affinity, and significantly inhibit the growth, metastasis and invasion of cancer cells expressing the tumor-specific antigen TM4SF5, and thus can be used for diagnosis, prevention or treatment of various cancers expressing TM4SF5.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: April 5, 2022
    Assignee: INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIVERSITY
    Inventors: Hyung Joo Kwon, Yong Sung Kim
  • Patent number: 11286301
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: March 29, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerlinde Wernig, Irving L. Weissman
  • Patent number: 11274281
    Abstract: The invention provides methods, compositions, uses and kits relating to exosomes isolated from progenitor cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 15, 2022
    Assignee: ReCyte Therapeutics, Inc.
    Inventors: Dana Larocca, Mohammad Hassanipour, Paola A. Bignone
  • Patent number: 11248048
    Abstract: Disclosed are an antibody to human programmed cell death 1 (PD-1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, an isolated cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer containing the same. The novel antibody binding to PD-1 or an antigen-binding fragment thereof can bind to PD-1 and inhibit the activity of PD-1, thus being useful for the development of immunotherapeutic agents for various diseases associated with PD-1.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: February 15, 2022
    Assignee: Y-BIOLOGICS INC.
    Inventors: Jae Eun Park, Soo Young Kim, Hyun Mi Lee, Si Hyung Lee, Hyun Kyung Lee, Hye-Nan Kim, Jin Chui Youn, Bum-chan Park, Jung Chae Lim, Young-Gyu Cho, Young Woo Park
  • Patent number: 11220544
    Abstract: The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or antigen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (“ICD”) of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypeptide is useful in a method of detecting or treating a condition or disease.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: January 11, 2022
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Luc Roland Desnoyers, Amy Grace DuPage
  • Patent number: 11124575
    Abstract: An Epidermal Growth Factor Receptor (EGFR, HER1, ErbB1)-binding agent has a heavy chain and a light chain, wherein the dimerization loop from EGFR's Domain II is grafted within complementarity determining region 3 (CDR3) of the heavy chain, and the binding agent is affinity matured. The graft directs the binding agent to bind EGFR at its dimerization region, to thereby inhibit EGFR dimerization and activation. In another embodiment, an EGFR-binding agent is panned out of Library F, a Fab library. The binding agents are for detecting and/or quantifying EGFR expression, for targeting EGFR-expressing cells, and for decreasing levels of EGFR in EGFR-expressing cells.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: September 21, 2021
    Assignees: University of Saskatchewan, The Governing Council of the University of Toronto
    Inventors: Sachdev Sidhu, Shane Miersch, Clarence Ronald Geyer
  • Patent number: 11123426
    Abstract: Methods for alleviating the suppression of humoral immunity by myeloid-dependent suppressor cells (MDSCs) are provided which include the administration of a VISTA antagonist and an iNOS/NO inhibitor in a subject in need thereof, e.g., subjects with cancer or infectious disease wherein VISTA is aberrantly expressed. This combination has been discovered to elicit a synergistic or additive effect on alleviating suppression of humoral immunity by VISTA which is elicited by MDSCs.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 21, 2021
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Kathy A. Green, Li Wang, Randolph J. Noelle, William R. Green
  • Patent number: 11118168
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 14, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11098109
    Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: August 24, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Daniel A. Vallera
  • Patent number: 11096962
    Abstract: The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 24, 2021
    Assignee: NANOBIOTIX
    Inventors: Julie Marill, Agnes Pottier, Laurent Levy
  • Patent number: 11098098
    Abstract: Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods. In certain embodiments the inflammatory diseases are not cancer-related. In various embodiments, the inflammatory diseases include, but are not limited to osteoporosis, obesity, metabolic syndrome, type 2 diabetes, fat liver, inflammatory bowel disease, chronic pancreatitis, asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), osteoarthritis, multiple sclerosis (MS), psoriasis, congestive heart failure (CHF), atherosclerosis, neurodegenerative diseases (ALS, Parkinson, Alzheimer's, Huntington disease), depression, schizophrenia, gout, asbestosis and silicosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 24, 2021
    Assignee: CureLab Oncology, Inc.
    Inventors: Alexander Shneider, Franco Venanzi, Dimitrios Agas, Antonio Concetti, Maria Giovanna Sabbieti, Vladimir Gabai, Michael Sherman, Victor Shifrin
  • Patent number: 11066442
    Abstract: Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: July 20, 2021
    Assignee: ENB Therapeutics, Inc.
    Inventor: Sumayah Jamal
  • Patent number: 11041212
    Abstract: A method of providing a prognosis or diagnosis of prostate cancer in a subject is described. The method includes obtaining a urine or prostate sample from the subject; determining the level of expression of ABCA1 in the sample; and comparing the level of expression of ABCA1 in the sample to the level of a control sample, wherein a decreased level of ABCA1 expression compared to the control indicates the subject has prostate cancer or a more severe form of prostate cancer. Methods of treating subjects identified as having prostate cancer, and kits for carrying out the method of prognosis or diagnosis are also described.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 22, 2021
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Angela H. Ting, Byron H. Lee
  • Patent number: 11034940
    Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 15, 2021
    Assignee: PRECIGEN, INC.
    Inventors: Rutul Shah, Peter Emtage, Ramya Yarlagadda
  • Patent number: 11028176
    Abstract: The present disclosure provides, inter alia, anti-peripheral lymph node addressin antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Reza Abdi
  • Patent number: 11028182
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 8, 2021
    Assignee: Zymeworks Inc.
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Patent number: 11008620
    Abstract: Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 18, 2021
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center
    Inventors: Pasi A. Janne, Jeffrey Engelman, Lewis C. Cantley
  • Patent number: 10995152
    Abstract: Polypeptide compositions comprising a human immunoglobulin constant region with a modified IgG4 hinge region having an N-terminal deletion of 1, 2, 3, 4, 5 amino acids, relative to a native human IgG4 hinge sequence are provided. In some embodiments the hinge sequence further comprises the amino acid substitution S228P (Eu numbering). Polypeptides comprising the modified sequence optionally comprise a binding moiety specific for an epitope that is present on red blood cells; and can provide for reduced agglutination of hematopoietic cells compared to a comparable polypeptide with a native hinge region.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 4, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jie Liu, Irving L. Weissman, Ravindra Majeti
  • Patent number: 10982001
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: April 20, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
  • Patent number: 10982000
    Abstract: The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: April 20, 2021
    Assignees: Novartis AG, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Anthony Rosenzweig, Jason D. Roh, David J. Glass
  • Patent number: 10975153
    Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: April 13, 2021
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
  • Patent number: 10975159
    Abstract: Novel compounds which bind specifically to human CD160, including a light chain variable domain (VL), a chosen sequence defined by SEQ ID No: 14 or SEQ ID No: 13 and a heavy chain variable domain (VH), a sequence chosen from SEQ ID No: 11, SEQ ID No: 25, SEQ ID No: 26, SEQ ID No: 27, SEQ ID No: 28, SEQ ID No: 29 or SEQ ID No: 30, fragments thereof or derivatives thereof.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 13, 2021
    Assignee: ELSALYS BIOTECH
    Inventors: Alexandre Calcei, Hélène Haegel, Thierry Menguy, Caroline Rozan
  • Patent number: 10973896
    Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 13, 2021
    Assignee: PCI Biotech AS
    Inventors: Anders Høgset, Pål Johansen
  • Patent number: 10927435
    Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R) with a DMARD.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: February 23, 2021
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Xiaohong Huang, Martine Jasson, Vanessa Marks, Allen Radin
  • Patent number: 10906981
    Abstract: Provided herein are compositions, kits, methods and systems related to administering a structure that crosses the blood brain barrier (BBB) along with a monosaccharide, either simultaneously or consecutively. The structure may be, for example an antibody or fusion antibody that binds to an insulin receptor.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: February 2, 2021
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10835618
    Abstract: The present invention relates to an isolated specific binding member capable of binding sialyl-di-Lewisa, and associated treatments and pharmaceutical compositions for treatment of cancer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Inventors: Lindy Gillian Durrant, Mireille Vankemmelbeke, Silvana Tivadar, Tina Parsons, Richard McIntosh
  • Patent number: RE49192
    Abstract: The present invention relates to an anti-CD19 antibody having a variant Fc region having some specific amino acid modifications relative to a wild-type Fc region which confer one or several useful effector functions. The present invention relates in particular to chimeric, humanized or full human anti-CD19 antibodies comprising such a variant Fc region. It relates advantageously to antibodies with an interesting and valuable glycosylation profile, especially a low fucose level and/or a high oligomannose level and low level of sialylated glycoform. The present invention also relates to the use of these antibodies in the treatment, prevention or management of disease or disorder, such as cancer, especially a B-cell malignancy, and auto-immune disease.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: August 30, 2022
    Assignee: INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH
    Inventors: Claudine Vermot-Desroches, Boris Sebastien Vuillermoz